Perindopril (DrugBank: Perindopril)
3 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
113 | Muscular dystrophy | 1 |
167 | Marfan syndrome | 2 |
222 | Primary nephrotic syndrome | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2000032525 | 2020-05-01 | 2020-05-01 | Early intervention for subclinical myocardial prevention of ACEI and beta-blocker in patients with Duchenne muscular dystrophy: a prospective multicenter randomized controlled clinical trial | Early intervention for subclinical myocardial prevention of ACEI and beta-blocker in patients with Duchenne muscular dystrophy: a prospective multicenter randomized controlled clinical trial | Duchenne muscular dystrophy | Group A:Perindopril;Group B:metoprolol;Group C:Perindopril and metoprolol; | West China Second University Hospital, Sichuan University | NULL | Recruiting | 1 | 18 | Male | Group A:106;Group B:106;Group C:106; | Phase 4 | China |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01295047 (ClinicalTrials.gov) | July 2006 | 11/2/2011 | Comparison of Medical Therapies in Marfan Syndrome. | Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial | Marfan Syndrome | Drug: Atenolol;Drug: VERAPAMIL;Drug: Perindopril | Cardiff University | NULL | Completed | 16 Years | 60 Years | Both | 18 | Phase 4 | United Kingdom |
2 | NCT00485368 (ClinicalTrials.gov) | January 2004 | 11/6/2007 | Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome | The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome. | Marfan Syndrome | Drug: Coversyl (perindopril) | Bayside Health | Baker Heart Research Institute;The Alfred | Completed | 18 Years | 40 Years | Both | 17 | Phase 3 | NULL |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR1900021757 | 2019-03-01 | 2019-03-08 | A randomized controlled trial for hydroxychloroquine sulfate in the treatment of idiopathic membranous nephropathy | The efficacy and safety of hydroxychloroquine sulfate in idiopathic membranous nephropathy: A randomized, controlled, Single-center clinical trial | Idiopathic Membranous Nephropathy | Group 1:Supportive treatment+Perindopril 8 mg/day;Group 2:Supportive treatment+Perindopril 8 mg/day+hydroxychloroquine sulfate (200mg 2/d);Group 3:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml);Group 4:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml)+hydroxychloroquine sulfate (200mg 2/d); | Nephrology Division, First Hospital Affiliated to Army Medical University | NULL | Recruiting | 18 | 60 | Both | Group 1:55;Group 2:55;Group 3:55;Group 4:55; | Phase 4 | China |